PDCD1 and non-small cell lung carcinoma: Induction of TRM cells can enhance the efficacy of cancer vaccines (11) and increase the response rate when using anti-PD-1 antibodies to reverse tumor-induced T cell exhaustion in NSCLC patients (12, 13).